Regeneron Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
Again for being here. I'm Brian Abrahams, 1 of the senior biotech analysts here at RBC Capital Markets. Our next feature company is Regeneron. And since I picked up coverage of the company, I'd be getting more and more questions about what's going on in Regeneron's pipeline? Of course, I get a lot of questions on EYLEA and Dupixent. But people I think are more and more interested in learning about the R&D engine.
And so we're really pleased to feature today, I think, a different aspect of Regeneron than many people get a chance to see and understand. We have with us Aris Baras, who's the Senior Vice President of the Regeneron's -- Regeneron Genetics Center, as well as Christos Kyratsous, the Senior Vice President of Research; and Ryan Crowe here on stage as well, who's their Vice President of Investor Relations. And they're going to walk us through a little bit more about what goes on behind the scenes at Regeneron that enables them to maintain 1 of the broadest pipelines in all of biotech. So thank
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |